{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Robello M"],"funding":["Intramural NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","National Cancer Institute","National Institutes of Health"],"pagination":["114763"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9664485"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["243"],"pubmed_abstract":["The wild-type p53 induced phosphatase 1 (Wip1), a member of the serine/threonine-specific PP2C family, is overexpressed in numerous human cancers. Wip1 dephosphorylates p53 as well as several kinases (such as p38 MAPK, ATM, Chk1, and Chk2) in the DNA damage response pathway that are responsible for maintaining genomic stability and preventing oncogenic transformation. As a result, Wip1 is an attractive target for synthetic inhibitors that could be further developed into therapeutics to treat some cancers. In this study, we report a series of alkyl-substituted N-methylaryl-N'-aryl-4-aminobenzamides and their inhibitory activity of the Wip1 phosphatase. A straightforward synthetic route was developed to synthesize the target compounds from commercially available starting materials. Three dif"],"journal":["European journal of medicinal chemistry"],"pubmed_title":["Alkyl-substituted N-methylaryl-N'-aryl-4-aminobenzamides: A new series of small molecule inhibitors for Wip1 phosphatase."],"pmcid":["PMC9664485"],"funding_grant_id":["Z01 DK031123","ZIA DK031143"],"pubmed_authors":["Robello M","Debnath S","Zheng H","Tagad HD","Appella E","Saha M","George Rosenker KM","Kumar JP","Appella DH","Mazur SJ"],"additional_accession":[]},"is_claimable":false,"name":"Alkyl-substituted N-methylaryl-N'-aryl-4-aminobenzamides: A new series of small molecule inhibitors for Wip1 phosphatase.","description":"The wild-type p53 induced phosphatase 1 (Wip1), a member of the serine/threonine-specific PP2C family, is overexpressed in numerous human cancers. Wip1 dephosphorylates p53 as well as several kinases (such as p38 MAPK, ATM, Chk1, and Chk2) in the DNA damage response pathway that are responsible for maintaining genomic stability and preventing oncogenic transformation. As a result, Wip1 is an attractive target for synthetic inhibitors that could be further developed into therapeutics to treat some cancers. In this study, we report a series of alkyl-substituted N-methylaryl-N'-aryl-4-aminobenzamides and their inhibitory activity of the Wip1 phosphatase. A straightforward synthetic route was developed to synthesize the target compounds from commercially available starting materials. Three dif","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-25T17:37:56.238Z","creation":"2025-04-25T17:37:56.238Z"},"accession":"S-EPMC9664485","cross_references":{"pubmed":["36179402"],"doi":["10.1016/j.ejmech.2022.114763"]}}